Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Wanbury Limited ( (IN:WANBURY) ).
Wanbury Limited’s board has approved the unaudited financial results for the quarter and nine months ending December 31, 2024. Additionally, the company plans to raise INR 175 crore through the issuance of non-convertible debentures in a private placement, and it has granted 200,000 stock options to employees under its ESOP 2016 scheme. These actions are likely to strengthen Wanbury’s financial position and incentivize its workforce, potentially enhancing its market competitiveness.
More about Wanbury Limited
Wanbury Limited operates in the pharmaceutical industry, focusing on the production and marketing of active pharmaceutical ingredients (APIs), formulations, and contract research and manufacturing services. The company primarily serves both domestic and international markets.
YTD Price Performance: -27.70%
Average Trading Volume: 22,819
Current Market Cap: 7.55B INR
Find detailed analytics on WANBURY stock on TipRanks’ Stock Analysis page.